Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00398411 · OUTCOME

Incidence of Clinically Significant Bacteremia

Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells · Source last updated 2015-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)

What was measured

Failure was defined as clinically significant bacteraemia occurring in the period of neutropenia and an intervention with a systemic antibacterial becoming necessary. With this being a discontinuation criteria and the outcome being measured at end of treatment, only one episode is taken into account for each participant.

Analysis population: intention to treat (ITT)

Groups in this outcome

Moxifloxacin

moxifloxacin 400 mg tablets once daily

Placebo

identical appearing placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Moxifloxacin34
Placebo32

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin3Not reportedNot reportedNot reportedNot reported
Placebo9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        9
denoms
  1. counts
    1. group Id
      OG000
      value
      34
    2. group Id
      OG001
      value
      32
    units
    Participants
description
Failure was defined as clinically significant bacteraemia occurring in the period of neutropenia and an intervention with a systemic antibacterial becoming necessary. With this being a discontinuation criteria and the outcome being measured at end of treatment, only one episode is taken into account for each participant.
groups
  1. description
    moxifloxacin 400 mg tablets once daily
    id
    OG000
    title
    Moxifloxacin
  2. description
    identical appearing placebo
    id
    OG001
    title
    Placebo
param Type
NUMBER
population Description
intention to treat (ITT)
reporting Status
POSTED
time Frame
end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)
title
Incidence of Clinically Significant Bacteremia
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice